剂量密集利妥昔单抗、大剂量甲氨蝶呤联合六周期CHOP-14方案对比一线自体移植治疗预后不良弥漫大B细胞淋巴瘤患者获得良好结局
这项10年单中心研究纳入63例连续治疗的年轻高危弥漫大B细胞淋巴瘤患者,比较两种治疗策略:队列1接受4周期R-CHOP-21后一线大剂量化疗联合自体干细胞支持,队列2接受6周期CHOP-14联合剂量密集利妥昔单抗和大剂量甲氨蝶呤。意向性分析显示队列2的2年无进展生存率和总生存率均显著优于队列1。
要点
- 队列1的2年无进展生存率和总生存率分别为60.6%和67.9%,39.4%的患者未 upfront 移植主要因早期进展(24.2%)。
- 队列2的总体缓解率为93.3%,完全缓解率为90%,2年无进展生存率和总生存率均为93.3%。
- 意向性分析中,队列2的2年无进展生存率(93.3% vs 60.6%,HR 7.2,P=0.009)和总生存率(93.3% vs 69.7%,HR 4.95,P=0.038)显著更优。
核心结论
- 年轻预后不良弥漫大B细胞淋巴瘤患者早期治疗强化后生存似乎更优。
研究设计与样本
- 10年单中心研究,纳入63例连续治疗的年轻中高危和高危年龄调整国际预后指数弥漫大B细胞淋巴瘤患者。
主要发现
- 队列1接受4周期R-CHOP-21后一线大剂量化疗联合自体干细胞支持,2年无进展生存率和总生存率分别为60.6%和67.9%。
- 队列1中39.4%的患者未 upfront 移植,主要因早期进展性疾病(24.2%)。
- 队列2接受6周期CHOP-14联合剂量密集利妥昔单抗和大剂量甲氨蝶呤,总体缓解率为93.3%,完全缓解率为90%,2年无进展生存率和总生存率均为93.3%。
- 意向性分析中,队列2对比队列1的2年无进展生存率为93.3% vs 60.6%(HR 7.2,P=0.009),总生存率为93.3% vs 69.7%(HR 4.95,P=0.038),差异显著。
- 多变量Cox回归模型调整aaIPI3后,队列2的无进展生存率(HR 8.12,95%CI 1.83-35.9,P=0.006)和总生存率(HR 5.86,95%CI 1.28-26.8,P=0.02)仍更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal therapeutic approach for young diffuse large B-cell lymphoma (DLBCL) patients with high-intermediate and high-risk age-adjusted international prognostic index (aaIPI) remains unknown. Hereby we report a 10-year single-centre study of 63 consecutively treated patients. To optimize outcome, two approaches were carried out: Cohort 1 patients received four cycles R-CHOP-21 (rituximab, cyclophosphamide, daunorubicin, vincristine, prednisolone over 21 days) followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT), resulting in 2-year progression-free (PFS) and overall survival (OS) of 60·6% and 67·9%. 39·4% of those patients were not transplanted upfront, mainly due to early progressive disease (24·2%). Cohort 2 patients received an early intensified protocol of six cycles of CHOP-14 (cyclophosphamide, daunorubicin, vincristine, prednisolone over 14 days) with dose-dense rituximab and high-dose methotrexate resulting in promising overall response- (93·3%) and complete remission (90%) rates and sustained survival (2-year PFS and OS: 93·3%). In an intention-to-treat analysis, 2-year PFS (60·6% vs. 93·3%, hazard ratio [HR] 7·2, P = 0·009) and OS (69·7% vs. 93·3%, HR 4·95, P = 0·038) differed significantly, in favour of the early intensified protocol (Cohort 2). In a multivariate Cox-regression model, PFS (HR 8·12, 95% confidence interval [CI] 1·83-35·9, P = 0·006) and OS (HR 5·86, 95% CI 1·28-26·8, P = 0·02) remained superior for Cohort 2 when adjusted for aaIPI3 as the most important prognostic factor. Survival of young poor-prognosis DLBCL patients appears superior after early therapy intensification.
引用
- Strüßmann T, Fritsch K, Baumgarten A, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Br J Haematol. 2017. PMID: 28643323. doi:10.1111/bjh.14802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。